[Israel O, Keidar Z, Bar-Shalom R. Positron emission tomography in the evaluation of lymphoma. Semin Nucl Med 2004; 3: 166-79.10.1053/j.semnuclmed.2004.03.002]Search in Google Scholar
[Matasar MJ, Zelenetz AD. Overview of lymphoma diagnosis and management. Radiol Clin N Am 2008; 46: 175-98.10.1016/j.rcl.2008.03.005]Search in Google Scholar
[Hoskin PJ. FDG PET in the management of lymphoma: a clinical perspective. Eur J Nucl Med 2002; 29: 449-51.10.1007/s00259-001-0755-4]Search in Google Scholar
[Weihrauch MR, Re D, Scheidhauer K, Ansen S, Dietlein M, Bischoff S, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98: 2930-4.10.1182/blood.V98.10.2930]Search in Google Scholar
[Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001; 115: 793-800.10.1046/j.1365-2141.2001.03147.x]Search in Google Scholar
[Lavely WC, Delbeke D, Greer JP, Morgan DS, Byrne DW, Price RR, et al. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys 2003; 57: 307-15.10.1016/S0360-3016(03)00599-6]Search in Google Scholar
[Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001; 115: 272-78.10.1046/j.1365-2141.2001.03169.x11703321]Search in Google Scholar
[Nordin AJ, Secondino S, Rahim NA, Pedrazzoli P, Siena S, Rossetti C, et al. Imaging in nasopharyngeal carcinoma: the value of 18-Florine Fluorodeoxyglucose PET/CT in comparison to conventional imaging modalities CT and MRI. Radiol Oncol 2009; 43: 247-57.10.2478/v10019-009-0026-8]Search in Google Scholar
[Avazpour I, Roslan RE, Bayat P, Saripan MI, Nordin AJ, Raja Abdullah RSA. Segmenting CT images of bronchogenic carcinoma with bone metastases using PET intensity markers approach. Radiol Oncol 2009; 43: 180-6.10.2478/v10019-009-0023-y]Search in Google Scholar
[de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK. 18 FDG - PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001; 12: 29-37.10.1023/A:1008357126404]Search in Google Scholar
[Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, et al. 18 F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 2006; 91: 522-9.]Search in Google Scholar
[Terasawa T, Nihashi T, Hotta T, Nagai H. 18 F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review. J Nucl Med 2008; 49: 13-21.10.2967/jnumed.107.03986718077527]Search in Google Scholar
[Schaefer NG, Taverna C, Strobel K, Wastl C, Kurrer M, Hany TF. Hodgkin disease: diagnostic value of FDG PET/CT after first line therapy - is biopsy of FDG - avid lesions still needed? Radiology 2007; 244: 257-62.10.1148/radiol.244106081017581905]Search in Google Scholar
[Poulou LS, Karianakis G, Ziakas PD. FDG PET scan strategies and long-term outcomes after first-line therapy in Hodgkin's disease. Eur J Radiol 2009; 70: 499-506.10.1016/j.ejrad.2008.01.04318342471]Search in Google Scholar
[Koga H, Sasaki M, Kuwabara Y, Nakagawa M, Hayashi K, Kaneko K, et al. Lesion detectability of a gamma camera based coincidence system with FDG in patients with malignant tumors: a comparison with dedicated positron emission tomography. Ann Nucl Med 2004; 18: 131-6.10.1007/BF0298510315195760]Search in Google Scholar
[Ak I, Blokland JA, Pauwels EK, Stokkel MP. The clinical value of 18F-FDG detection with a dual-head coincidence camera: a review. Eur J Nucl Med 2001; 28: 763-78.10.1007/s00259010050124777543]Search in Google Scholar
[Torizuka T, Nakamura F, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2004; 31: 22-8.10.1007/s00259-003-1333-814574514]Search in Google Scholar
[Schoder H, Moskowitz C. PET imaging for response assessment in lymphoma: potential and limitations. Radiol Clin N Am 2008; 46: 225-41.10.1016/j.rcl.2008.04.00218619378]Search in Google Scholar
[Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244-53.10.1200/JCO.1999.17.4.124410561185]Search in Google Scholar
[Grošev D, Lončarić S, Vandenberghe S, Dodig D. Triple-head gamma camera PET: system overview and performance characteristics. Nucl Med Commun 2002; 23: 809-14.10.1097/00006231-200208000-0001612124488]Search in Google Scholar
[Grošev D. Performance characteristics of gamma cameras - Reply. [Letter] Nucl Med Commun 2003; 24: 440.10.1097/00006231-200304000-00016]Search in Google Scholar
[Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008; 112: 3989-94.10.1182/blood-2008-06-155820258198418757777]Search in Google Scholar
[Castellucci P, Zinzani P, Pourdehnad M, Alinari L, Nanni C, Farsad M, et al. 18F-FDG PET in malignant lymphoma: significance of positive findings. Eur J Nucl Med Mol Imaging 2005; 32: 749-56.10.1007/s00259-004-1748-x15785956]Search in Google Scholar
[Kasamon YL, Jones RJ, Wahl RL. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med 2007; 48 Suppl 1:19S-27S.]Search in Google Scholar
[Barrington SF, O'Doherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging 2003; 30: S117-27.10.1007/s00259-003-1169-212748831]Search in Google Scholar